Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Cash & Equivalents: 2013-2024

Historic Cash & Equivalents for Surgery Partners (SGRY) over the last 11 years, with FY2024 value amounting to $269.5 million.

  • Surgery Partners' Cash & Equivalents fell 829.58% to $203.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $203.4 million, marking a year-over-year decrease of 829.58%. This contributed to the annual value of $269.5 million for FY2024, which is 3757.02% up from last year.
  • Surgery Partners' Cash & Equivalents amounted to $269.5 million in FY2024, which was up 3757.02% from $195.9 million recorded in FY2023.
  • In the past 5 years, Surgery Partners' Cash & Equivalents registered a high of $389.9 million during FY2021, and its lowest value of $195.9 million during FY2023.
  • For the 5-year period, Surgery Partners' Cash & Equivalents averaged around $291.2 million, with its median value being $282.9 million (2022).
  • Per our database at Business Quant, Surgery Partners' Cash & Equivalents soared by 24293.42% in 2020 and then crashed by 3075.29% in 2023.
  • Annual analysis of 5 years shows Surgery Partners' Cash & Equivalents stood at $317.9 million in 2020, then rose by 22.65% to $389.9 million in 2021, then decreased by 27.44% to $282.9 million in 2022, then tumbled by 30.75% to $195.9 million in 2023, then surged by 37.57% to $269.5 million in 2024.
  • Its Cash & Equivalents stands at $269.5 million for FY2024, versus $195.9 million for FY2023 and $282.9 million for FY2022.